|
|
|
| Analysis of clinical efficacy, safety and prognosis of docetaxel combined with nedaplatin in local advanced nasopharyngeal carcinoma |
| LIU Tongxin SUN Quanquan CHEN Jing LI Bin QIN Weifeng WANG Fangzheng FU Zhenfu HU Fujun |
| Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Province, Hangzhou 310022, China |
|
|
|
Abstract Objective To evaluate the efficacy and safety of Docetaxel combined with Nedaplatin (TP) and Fluorouracil combined with Cisplatin (PF) in the treatment of locally advanced nasopharyngeal carcinoma. Methods Retrospective analysis of 271 patients who received TP or PF induction chemotherapy in Zhejiang Cancer Hospital from January 2012 to May 2014, 8 cases were lost to follow-up, and 263 cases were finally included in the analysis, including 92 cases in PF group and 171 cases in TP group. Efficacy, safety and prognosis of the two groups were compared. Results The 5-year overall survival rate (OS), progression-free survival rate (PFS), local recurrence free survival rate (LRFS), and distant metastasis free survival rate (DMFS) were compared, the differences were not statisticdly significant between the two groups (all P ＞ 0.05). Further multivariate analysis showed that N staging was an independent prognostic factor for 5-year OS, PFS and DMFS (P ＜ 0.05). Adverse reaction analysis showed that grade 3-4 leukopenia, neutrophilia and thrombocytopenia were more likely to occur in the TP group, while grade 3-4 nausea and vomiting were more likely to occur in the PF group, with statistically significant differences (P ＜ 0.05). There were no statistically significant differences in other adverse reactions between the two groups (P ＞ 0.05). Conclusion The efficacy of TP and PF induction chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma is similar, and the adverse reactions are tolerable, which can be used in the treatment of locally advanced nasopharyngeal carcinoma.
|
|
|
|
|
|
[1] Cao SM，Simons MJ，Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China [J]. Chin J Cancer，2011，30（2）：114-119.
[2] Lee AW，Sze WM，Au JS，et al. Treatment results for nasopharyngeal carcinoma in the modern era：the Hong Kong experience [J]. Int J Radiat Oncol Biol Phys，2005，61（4）：1107-1116.
[3] Shah BA，Qureshi MM，Jalisi S，et al. Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network （NCCN） guidelines [J]. Pract Radiat Oncol，2016，6（4）：248-254.
[4] Lin JC，Liang WM，Jan JS，et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate? [J]. Int J Radiat Oncol Biol Phys，2004，60（1）：156-164.
[5] Edge SB，Compton CC. The American Joint Committee on Cancer：the 7th edition of the AJCC cancer staging manual and the future of TNM [J]. Ann Surg Oncol，2010，17（6）：1471-1474.
[6] Lee N，Harris J，Garden AS，et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma：radiation therapy oncology group phase Ⅱ trial 0225 [J]. J Clin Oncol，2009，27（22）：3684-3690.
[7] Al-Sarraf M，Leblanc M，Giri PG，et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer：phase Ⅲ randomized Intergroup study 0099 [J]. J Clin Oncol，1998，16（4）：1310-1317.
[8] 马骏.鼻咽癌治疗的研究进展[J].中山大学学报：医学科学版，2010，31（2）：179-185.
[9] 徐云华，杜伟，童涛，等.诱导化疗对局部晚期鼻咽癌放疗远期疗效的影响[J].现代肿瘤医学，2010，18（7）：1294-1295.
[10] Lee AW，Lau KY，Hung WM，et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma [J]. Radiother Oncol，2008，87（2）：204-210.
[11] Hareyama M，Sakata K，Shirato H，et al. A prospective，randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma [J]. Cancer，2002，94（8）：2217-2223.
[12] Tang LQ，Chen DP，Guo L，et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma：an open-label，non-inferiority，randomised phase 3 trial [J]. Lancet Oncol，2018， 19（4）：461-473.
[13] Liu T，Sun Q，Chen J，et al. Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma：a Retrospective Study [J]. J Cancer，2018，9（20）：3676-3682.
[14] Herman LC，Chen L，Garnett A，et al. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer [J]. Oral Oncol，2014，50（1）：52-58.
[15] Sun Y，Li WF，Chen NY，et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：a phase 3，multicentre，randomised controlled trial [J]. Lancet Oncol，2016，17（11）：1509-1520.
[16] Kong L，Zhang Y，Hu C，et al. Effects of induction docetaxel，platinum，and fluorouracil chemotherapy in patients with stage Ⅲ or ⅣA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy：Final results of 2 parallel phase 2 clinical trials [J]. Cancer，2017，123（12）：2258-2267.
[17] Ou X，Zhou X，Shi Q，et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy：new insight into the value of total dose of cisplatin and radiation boost [J]. Oncotarget，2015，6（35）：38381-38397.
[18] Wang FZ，Jiang CE，Wang L，et al. Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma [J]. Oncotarget，2017，8（53）：91 150-91 161.
[19] 马雄辉，梁彩霞，江丹贤，等.TPF诱导化疗或PF诱导化疗联合同期放化疗治疗局部晚期鼻咽癌的临床观察[J].中国癌症杂志，2016，26（12）：1018-1024.
[20] Xu J，He X，Cheng K，et al. Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma：Survival and toxicity [J]. Head Neck，2014，36（10）：1474-1480. |
|
|
|
